切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (04) : 487 -491. doi: 10.3877/cma.j.issn.2095-3232.2024.04.008

所属专题: 述评 综述

专家论坛

胰腺腺泡细胞癌诊断与治疗
武帅1, 吴佼星1, 王方舟1, 杨沛泽1, 董顺斌1, 王铮1, 仵正1,()   
  1. 1. 710061 西安交通大学第一附属医院肝胆外科
  • 收稿日期:2024-03-30 出版日期:2024-08-10
  • 通信作者: 仵正
  • 基金资助:
    陕西省科技资源开放共享平台(2022PT-35)

Diagnosis and treatment of pancreatic acinar cell carcinoma

Shuai Wu1, Jiaoxing Wu1, Fangzhou Wang1, Peize Yang1, Shunbin Dong1, Zheng Wang1, Zheng Wu1,()   

  1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
  • Received:2024-03-30 Published:2024-08-10
  • Corresponding author: Zheng Wu
引用本文:

武帅, 吴佼星, 王方舟, 杨沛泽, 董顺斌, 王铮, 仵正. 胰腺腺泡细胞癌诊断与治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 487-491.

Shuai Wu, Jiaoxing Wu, Fangzhou Wang, Peize Yang, Shunbin Dong, Zheng Wang, Zheng Wu. Diagnosis and treatment of pancreatic acinar cell carcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 487-491.

胰腺腺泡细胞癌(PACC)是来源于胰腺上皮的恶性肿瘤,因其发病率较低而在临床上少见,且无特异性临床表现。国内外报道PACC仅占胰腺外分泌肿瘤的1%~2%,占胰腺恶性肿瘤的0.44%。该病具有诊断困难、手术可切除性低、易转移的特点,但预后优于胰腺导管腺癌,认识及掌握PACC的临床诊治可以提高其诊断率并改善预后。

Pancreatic acinar cell carcinoma (PACC) is a malignant epithelial tumor arising from pancreatic epithelium, which is rare in clinical practice due to low incidence, and it has no specific clinical manifestations. Previous studies have reported that PACC accounts for merely 1%-2% of exocrine pancreatic tumors and 0.44% of pancreatic malignant tumors. This disease is challenging to diagnose, has low resection rates, and easily metastasizes. However, the prognosis is better than that of pancreatic ductal adenocarcinoma. Understanding and mastering clinical diagnosis and treatment of PACC can improve diagnostic rate and clinical prognosis.

图1 PACC增强CT和MRI表现注:a、b、c分别为增强CT的动脉期、静脉期和延迟期,d、e、f分别为增强MRI的动脉期、静脉期和延迟期;PACC为胰腺腺泡细胞癌
图2 PACC病理学表现注:肿瘤呈腺泡状或实性结构,腺泡状结构由大小不一的细胞组成,嗜酸性颗粒状细胞质(100× HE染色);PACC为胰腺腺泡细胞癌
表1 单纯性PACC诊断要点
[1]
Paseiro-Crespo G, García-Nebreda M, Roldán Cortés D, et al. Primary pure pancreatic-type acinar cell carcinoma of the stomach: a rare entity with a difficult diagnosis and review of the literature[J]. Int J Surg Pathol, 2022, 30(5):528-538.
[2]
Kim KM, Kim CY, Hong SM, et al. A primary pure pancreatic-type acinar cell carcinoma of the stomach: a case report[J]. Diagn Pathol, 2017, 12(1):10.
[3]
Petrova E, Wellner J, Nording AK, et al. Survival outcome and prognostic factors for pancreatic acinar cell carcinoma: retrospective analysis from the German cancer registry group[J]. Cancers, 2021, 13(23):6121.
[4]
Chaudhary P. Acinar cell carcinoma of the pancreas: a literature review and update[J]. Indian J Surg, 2015, 77(3):226-231.
[5]
Ciardiello D, Urbano F, Zamboni G, et al. Left abdominal mass with carcinosis: unusual presentation of pancreatic acinar cell carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2023, 22(4):412-414.
[6]
Al-Hader A, Al-Rohil RN, Han H, et al. Pancreatic acinar cell carcinoma: a review on molecular profiling of patient tumors[J]. World J Gastroenterol, 2017, 23(45):7945-7951.
[7]
Singh S, Gorouhi F, Konia T, et al. Pancreatic acinar cell carcinoma-induced panniculitis[J]. JAAD Case Rep, 2018, 4(7):719-721.
[8]
la Rosa S, Adsay V, Albarello L, et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers[J]. Am J Surg Pathol, 2012, 36(12):1782-1795.
[9]
Chen H, Xu Z, Shen Z, et al. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal adenocarcinoma[J]. Eur J Surg Oncol, 2022, 48(5):1062-1067.
[10]
Baek KA, Kim SS, Lee HN. Typical CT and MRI features of pancreatic acinar cell carcinoma: main teaching point: typical imaging features of pancreatic acinar cell carcinoma are relatively large, with a well-defined margin, exophytic growth, and heterogeneous enhancement[J]. J Belg Soc Radiol, 2019, 103(1):43.
[11]
Luo Y, Hu G, Ma Y, et al. Acinar cell carcinoma of the pancreas presenting as diffuse pancreatic enlargement: two case reports and literature review[J]. Medicine, 2017, 96(38):e7904.
[12]
Busch E, Werft W, Bougatf N, et al. Metastatic acinar cell carcinoma of the pancreas: a retrospective cohort study on systemic chemotherapy and review of the literature[J]. Pancreas, 2021, 50(3):300-305.
[13]
Uemura S, Maeda H, Tanioka N, et al. Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: a case report[J]. Cancer Rep, 2022, 5(9):e1648.
[14]
Sridharan V, Mino-Kenudson M, Cleary JM, et al. Pancreatic acinar cell carcinoma: a multi-center series on clinical characteristics and treatment outcomes[J]. Pancreatology, 2021: S1424-S3903(21)00162-9.
[15]
Xu JY, Guan WL, Lu SX, et al. Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature[J]. Clin Med Insights Oncol, 2022, 16: 11795549221090186.
[16]
Dreikhausen L, Schulte N, Belle S, et al. Pancreatic acinar cell carcinoma with germline BRCA2 mutation and severe pancreatic panniculitis: a case report[J]. Visc Med, 2021, 37(5):447-450.
[17]
Kryklyva V, Haj Mohammad N, Morsink FHM, et al. Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review[J]. Cancer Biol Ther, 2019, 20(7):949-955.
[18]
Gupta M, Sherrow C, Krone ME, et al. Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature[J]. J Natl Compr Canc Netw, 2021, 19(1):10-15.
[19]
Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma[J]. Surgery, 2008, 144(2):141-148.
[20]
Nie D, Shi B, Zhang T, et al. The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: a population-based study[J]. PLoS One, 2020, 15(12):e0243164.
[21]
Schmidt CM, Matos JM, Bentrem DJ, et al. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma[J]. J Gastrointest Surg, 2008, 12(12):2078-2086.
[1] 孙辉, 李长霖. 分化型甲状腺癌根治性切除术中的关键考量与策略[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 477-481.
[2] 王宇, 徐芳泉, 周旋, 姚晓峰, 李强. 不断提高分化型甲状腺癌根治性切除规范化[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 473-476.
[3] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[4] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[5] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[6] 韦德令, 蒋佳君, 徐邦浩, 王继龙, 朱海, 卢婷婷, 张灵, 曾晶晶, 郭雅, 文张. 显微外科肝动脉重建在累及第一肝门胆管癌外科治疗的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 350-356.
[7] 王健东, 全志伟. 重视胆道恶性肿瘤化疗联合靶向免疫的综合治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 125-130.
[8] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[9] 陈立华. 中小型前庭神经鞘瘤治疗方式选择的原则和依据[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(01): 1-7.
[10] 杜莹, 曹莉莉. 新辅助化疗在结直肠癌治疗中的应用[J/OL]. 中华消化病与影像杂志(电子版), 2023, 13(01): 39-45.
[11] 陆知非, 华永飞, 姜哲康, 高过, 江寅, 王高卿. 初始不可切除肝癌转化治疗的影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 268-274.
[12] 中国抗癌协会食管癌专业委员会. 机器人辅助食管切除术中国临床专家共识(2023版)[J/OL]. 中华胸部外科电子杂志, 2024, 11(01): 1-15.
[13] 王睿, 杨建军, 宋致成, 顾岩. 重视肥胖合并食管裂孔疝外科治疗的特殊性[J/OL]. 中华胃食管反流病电子杂志, 2023, 10(04): 191-195.
[14] 郭明杰, 周春起, 余佳慧, 李世红, 朱红梅, 刘雁军, 杨华武. 肥胖与胃食管反流病的关系及减重术后反流治疗研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 184-192.
[15] 周彪, 李政奇, 孟化. 肥胖与内镜下减重治疗研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 100-107.
阅读次数
全文


摘要